Monoferric denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for monoferric are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Applies Quantity Limits to Monoferric

Monoferric (ferric derisomaltose) is an IV iron formulation typically administered as one or two infusions to replenish iron stores. Aetna's quantity limits for IV iron products reflect the standard treatment course as described in the FDA-approved prescribing information and clinical guidelines. Denials on this basis typically arise when a prescriber requests a quantity, frequency, or cumulative dose that exceeds what Aetna considers standard, without documentation explaining the clinical reason for the higher quantity.

## Why This Denial Is Appealable

Quantity limit denials are appealable when there is a documented clinical reason the standard quantity is insufficient — for example, ongoing blood loss from a chronic condition, malabsorption that limits iron uptake and requires repeat repletion, or a clinical severity that requires a loading approach the prescriber has individualized. The appeal must explain the clinical rationale in the patient's specific context, tied to chart documentation.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal within the timeframe on your denial letter. Quantity-limit denials are adverse benefit determinations and entitled to full-and-fair review.
• External review (ACA §2719): If the internal appeal is denied or not resolved in time, an independent external reviewer — not Aetna — can issue a binding determination. The window is approximately 4 months from the final internal denial.
• Expedited review: Available for urgent situations; 72-hour turnaround.

## Documentation to Gather

1. Prescriber's treatment plan — documenting the intended number of infusions and the clinical rationale for the requested quantity. 2. Underlying condition documentation — records explaining any ongoing cause of iron deficiency (e.g., chronic GI blood loss, renal disease, malabsorption) that creates a need for repeat treatment. 3. Prior response records — if you have received IV iron before, document the response and any recurrence that supports additional dosing. 4. FDA-approved label — confirm that your prescriber's proposed regimen is consistent with or clinically justified relative to the label. 5. Prescriber medical-necessity letter — explicitly stating why the requested quantity is medically necessary for this patient.

## Criteria-Mapping Structure

Request Aetna's quantity-limit policy for IV iron products. Identify the exact limit being applied and the criteria for exceptions. Your appeal packet should address each exception criterion with a specific chart fact. If the quantity is within the FDA label range and Aetna's limit is more restrictive, note that discrepancy in the appeal letter and ask the reviewer to reconcile it with the FDA-approved prescribing information.